Recruiting
Phase 1

A Study of SIPLIZUMAB in AILD and LT Patients

Sponsor:

Elizabeth C. Verna

Code:

NCT06455280

Conditions

Autoimmune Liver Disease

Liver Transplant Disorder

Autoimmune Hepatitis

Primary Sclerosing Cholangitis

End Stage Liver DIsease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Siplizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information